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Abstract
Adherence to a drug regimen can be a strong predictor of health outcomes, and validated measures 
of adherence are necessary at all stages of therapy from drug development to prescription. Many of 
the existing metrics of drug adherence (e.g., self-report, pill counts, blood monitoring) have 
limitations, and analysis of hair strands has recently emerged as an objective alternative. 
Traditional methods of hair analysis based on LC–MS/MS (segmenting strands at ≥1 cm length) 
are not capable of preserving a temporal record of drug intake at higher resolution than 
approximately 1 month. Here, we evaluated the detectability of HIV antiretrovirals (ARVs) in hair 
from a range of drug classes using infrared matrix-assisted laser desorption electrospray ionization 
(IR-MALDESI) mass spectrometry imaging (MSI) with 100 µm resolution. Infrared laser 
desorption of hair strands was shown to penetrate into the strand cortex, allowing direct 
measurement by MSI without analyte extraction. Using optimized desorption conditions, a linear 
correlation between IR-MALDESI ion abundance and LC–MS/MS response was observed for six 
common ARVs with estimated limits of detection less than or equal to 1.6 ng/mg hair. The 
distribution of efavirenz (EFV) was then monitored in a series of hair strands collected from HIV 
infected, virologically suppressed patients. Because of the role hair melanin plays in accumulation 
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of basic drugs (like most ARVs), an MSI method to quantify the melanin biomarker pyrrole-2,3,5-
tricarboxylic acid (PTCA) was evaluated as a means of normalizing drug response between 
patients to develop broadly applicable adherence criteria.
Graphical Abstract
Adherence to antiretroviral (ARV) therapy is critical for achieving HIV RNA suppression in 
HIV-infected patients1–3 and for preventing HIV acquisition in uninfected individuals using 
pre-exposure prophylaxis (PrEP).4 Yet a high level of adherence is challenging for HIV-
infected individuals on life-long ARVs and for HIV-negative individuals using daily PrEP 
who are not at daily risk for HIV acquisition. Poor adherence was primarily responsible for a 
lack of drug effectiveness in multiple recent double-blind, placebo-controlled PrEP 
studies.5–7 These studies found that counting product returns and using patient self-report 
significantly overpredicted adherence as measured by ARV concentrations in blood plasma 
or cells. Since the consequences of poor or intermittent adherence are significant, valid 
measures of adherence are critical for optimizing the effectiveness of both HIV treatment 
and prevention, in both the clinic and research settings. Hair has long been a targeted 
analysis matrix for forensic monitoring of drug abuse8,9 because its temporal record (weeks–
months) provides a longer term for retrospective analysis than other human matrixes and is 
being increasingly utilized for therapeutic drug monitoring.10,11
Currently, the disposition of ARVs in hair is measured by LC–MS/MS analysis.12,13 This 
approach represents the current “gold standard” and has been correlated with adherence in 
PrEP14 and with health outcomes in treatment.15,16 While LC–MS/MS methods are sensitive 
and specific, these techniques require multiple (e.g., 25–100) strands of at least 1 cm in 
length to be combined for a single measurement. This approach effectively averages drug 
response over a month’s time based on growth rates for hair in the active, anagen, phase of 
hair growth9 and cannot differentiate strict adherence to therapy at regular dosing intervals 
from heterogeneous adherence. The admixture of various exposures within such a 
homogenate can lead to hybrid hair drug concentration which may over- or underestimate 
drug exposure at any one point in time. Given that periodic self-imposed cessation from 
treatment (“drug holidays”) for periods greater than 48 h can be associated with rebounding 
viral loads17 and treatment failure due to development of drug resistance,18 a smaller 
temporal window of adherence monitoring would be beneficial to inform evaluation of drug 
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efficacy and strategy for care. Additionally, LC–MS/MS methods have a potentially 
burdensome requirement for quantity of donated hair and necessitate a time intensive sample 
preparation.
Mass spectrometry imaging (MSI) of biological samples offers an alternative analytical 
approach providing the capability for simultaneously monitoring the spatial distribution of 
analytes ranging from small molecules, such as pharmaceutical drugs,19 to lipids20,21 to 
peptides and proteins.22 The utility of MSI has been demonstrated for a variety of fields, 
with particular emphasis on biomedical applications like drug distribution23 and biomarker 
identification.24 While such studies predominately target biological tissue as a sample 
matrix, recent work has investigated the distribution of pharmaceuticals,25 drugs of 
abuse,26–29 and endogenous biomolecules30 in hair using multiple MSI techniques.
In this work, we extend the application of infrared matrix-assisted laser desorption 
electrospray ionization (IR-MALDESI),31 which we have demonstrated to be a sensitive 
MSI technique for the analysis of ARVs in biological tissue,32–34 to the morphologically 
distinct matrix of hair. The technique couples resonant laser desorption with electrospray 
postionization for a soft, ESI-like ionization mechanism. Unlike MALDI, the traditional 
approach for MSI, IR-MALDESI does not require an organic matrix to promote analyte 
desorption and ionization, which can interfere with the analysis of small molecules such as 
ARVs. Instead, a layer of ice deposited on the sample is used as an energy-absorbing matrix 
for infrared radiation that is easily applied and does not contribute to the background MS 
response. An evaluation of variables controlling the desorption of material from a single hair 
strand was performed to maximize analyte response by IR-MALDESI. These conditions 
were then used to determine the IRMALDESI response to a broad range of ARVs 
representing several drug classes, which has been correlated to LC–MS/MS analyses for 
concentrations ranging 3 orders of magnitude. The distribution of ARVs within single hair 
strands collected from HIV+ patients on active ARV therapy is evaluated here for the first 
time.
Additionally, an MSI method for determining relative hair melanin content is demonstrated, 
providing a critical means of comparing drug exposure in hair strands collected from 
different patients. During the hair growth process, averaging 1 cm per month on the scalp, 
three factors predominately contribute to the incorporation of drug in hair strands: drug 
basicity, drug lipophilicity, and hair melanin content.9 The former two physicochemical 
attributes of the drug control its ability to penetrate cellular membranes of hair, where the 
drug then binds to melanin. Hence, preferential accumulation has been observed for 
lipophilic and basic drugs in pigmented hair strands, with drug concentration correlating 
with melanin concentration35–37 or otherwise present among race groups possessing higher 
melanin in hair.38 Here, we examine a MSI hair sample preparation step to oxidize and 
chemically degrade polymeric melanin into smaller molecules used as direct markers of 
pigmentation.39–41 We show that normalizing drug response in hair based on melanin 
content can facilitate comparison of drug response in hair between patients.
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EXPERIMENTAL SECTION
Materials
Antiretroviral reference compounds emtricitabine (FTC), tenofovir (TFV), efavirenz (EFV), 
dolutegravir (DTG), raltegravir (RAL), darunavir (DRV), maraviroc (MRV), and lamivudine 
(3TC) were obtained through the NIH AIDS Reagent Program. Pyrrole-2,3,5-tricarboxylic 
acid (PTCA) acetic acid salt was purchased from Toronto Research Chemicals (Toronto, 
Ontario, CAN). Internal standard components FTC-13C15N2 and TFV-13C5 were purchased 
from Moravek Biochemicals (CA), 3TC-15N-d2 and DRV-d9 from Aptochem (Montreal, 
Canada), and RAL-d3 and MVC-d6, from Toronto Research Chemicals (Toronto, Canada). 
HPLC grade methanol and formic acid were purchased from Fisher Scientific (PA). 
Hydrogen peroxide (30%) was purchased from VWR International (PA). All materials were 
used without further purification.
Hair Samples
Sample collection occurred in accordance with Good Clinical Practice procedures, all 
applicable regulatory requirements, and the guiding principles of the Declaration of 
Helsinki. The study protocol was approved by the Biomedical Institutional Review Board at 
the University of North Carolina at Chapel Hill (IRBIS 08-0047), and all subjects provided 
written informed consent before study entry. Hair strands collected from a healthy donor not 
on HIV therapy were used both as negative controls and also as a blank hair matrix for 
incubation in a solution of ARVs. Blank hair was incubated in 1 mL of tissue culture media 
[Iscove’s Modified Dulbecco’s Media (Gibco, Grand Island, NY), 10% fetal bovine serum 
(Gibco), 240 units/mL nystatin (Sigma, St. Louis, MO), 100 units/mL penicillin-
streptomycin (Gibco), and MEM vitamin solution (Sigma)] containing 6 ARVs (EFV, DTG, 
RAL, DRV, MRV, 3TC) ranging in concentration over 3 logs (1, 10, 100 µg/mL) for 24 h at 
37 °C, allowing penetration of drug into the hair matrix, before the incubated strands were 
rinsed surficially with methanol/water and dried. ARV-incubated hair strands were used to 
optimize IR-MALDESI desorption conditions and calibrate instrument response to ARVs in 
hair. Hair strands were also collected at the UNC Clinical and Translational Research Center 
from HIV+, virologically suppressed subjects (<50 copies/ml RNA by PCR) receiving 
Atripla (a fixed dose combination of EFV, FTC, and prodrug form of TFV) for ≥1 year. Hair 
was collected from the occipital region of the scalp by lifting the top layer of hair and 
clipping 20–30 fibers of hair at least 1 cm long from as close to the scalp as possible. All 
hair samples were stored in aluminum foil and sealed in a plastic bag with desiccant until 
analysis.
Sample Preparation
Hair samples were adhered to glass microscope slides using double-sided adhesive tape 
without any prewashing. No solvent extraction step or sample manipulation was undertaken 
prior to MSI analysis when targeting disposition of ARVs in hair. For analysis of PTCA as a 
marker of eumelanin content in hair, sample-mounted slides were sprayed with a solution of 
15% hydrogen peroxide and 1 M NH4OH in 50/50 (v/v) methanol/water using a thermal-
assisted pneumatic sprayer (TM Sprayer, LEAP Technologies) and allowed to incubate on a 
lab bench at room temperature for 24 h prior to analysis.
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IR-MALDESI Mass Spectrometry Imaging
The components and working principles of the IR-MALDESI MSI source used in this work 
have been detailed elsewhere,42 based on the original source design31 and will be described 
here briefly. Sample slides for analysis were placed onto a Peltier-cooled sample stage where 
a controlled layer of ice was allowed to deposit onto the sample surface, which has been 
shown to enhance observed IR-MALDESI ion abundances.43 The ice layer thickness was 
maintained throughout analysis by holding the relative humidity in the source enclosure at 
10% using a low flow of dry nitrogen gas. A 100 Hz IR Opolette HR infrared OPO laser 
(Opotek, Carlsbad, CA) tuned to the asymmetric stretching vibrational mode of liquid water 
(λ = 2.94 µm) was used to desorb sample material. The plume of neutral material generated 
by laser desorption of the sample expanded upward from the stage and was ionized with an 
orthogonal electrospray plume in an ESI-like fashion.44,45 Positive polarity experiments 
were conducted using a 50/50 (v/v) solution of methanol/water with 0.2% formic acid as the 
electrospray solvent. For polarity switching experiments, a 20 mM ammonium hydroxide 
modifier was used with the 50/50 (v/v) solution of methanol/water, as has been used 
previously.46 A recent evaluation of solvent modifiers for polarity switching experiments, 
conducted after the work presented here was performed, indicates that increased ion 
abundance is gained when using an acetic acid modifier without bias of response between 
positive and negative ionization modes47 and will be utilized in future work. Spatial 
resolution of 100 µm was achieved from the ~250 µm diameter laser spot by translating the 
two-axis stage in 100 µm increments based on an oversampling approach.48 Resulting voxel 
dimensions for positive polarity experiments (100 µm × 100 µm) represent a theoretical 
temporal window of approximately 7 h based on an average growth rate of 1 cm per month. 
The method of data acquisition for polarity switching elongates the voxel dimension along 
one axis (200 µm × 100 µm) since the measurement polarity is alternated between sampling 
points across a scanline. The IR-MALDESI imaging source was fully synchronized with a 
Thermo Fisher Scientific Q Exactive Plus mass spectrometer (Bremen, Germany). The Q 
Exactive Plus was operated in full scan mode with a mass range m/z 150–600, with mass 
resolving power set to 140 000 (fwhm, m/z 200). Since AGC is turned off during IR-
MALDESI experiments, lock masses are utilized in the control software to achieve parts per 
million mass accuracy.49 For positive ionization mode two peaks of an ambient ion, 
diisooctyl phthalate, at m/z 391.2843 [M + H]+ and m/z 413.2662 [M + Na]+ were used as 
lock masses. The peaks of palmitic acid at m/z 255.2329 [M − H]− and stearic acid at m/z 
283.2643 [M − H]− were used as lock masses in negative ionization mode. MS2 imaging 
(MS2I) of PTCA ([M − H]− m/z 198.0039) was conducted with a 0.5 m/z window centered 
at m/z 198.00 followed by ion accumulation in the C-trap. The accumulated ion packet was 
fragmented in the HCD cell at a normalized collision energy of 10% and then analyzed with 
mass resolving power of 140 000 (fwhm, m/z 200). All Thermo RAW files were converted 
first to mzML50 and then imzML51 file formats before data processing and analysis of MSI 
data using MSiReader.52 Ion maps were created with a mass tolerance of 5 ppm, and sample 
dimensions are indicated by scale bars.
LC–MS/MS Analysis of Hair
Extraction of analytes from snippets (1–2 cm) of incubated hair strands and from intact (3–
3.5 cm) dosed hair strands was performed at room temperature by 10 min of sonication and 
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20 min of vortexing in 0.300 mL of 70:30 methanol/water. Following extraction, the samples 
were mixed with isotopically labeled internal standards (FTC-13C15N2, 3TC-15N-d2, 
TFV-13C5, RAL-d3 (for RAL and DTG quantitation), MVC-d6, and DRV-d9 (for DRV and 
EFV quantitation)). Sample extracts were then evaporated to dryness and reconstituted in 
90:10 water/methanol. A Shimadzu HPLC system performed chromatographic separation 
with a Waters Atlantis T3 (50 mm × 2.1 mm, 3 µm) analytical column under gradient 
conditions. An AB SCIEX API 5000 mass spectrometer (AB SCIEX, Foster City, CA) 
equipped with a turbo spray interface was used as the detector. The samples were analyzed 
with a set of calibration standards and QC samples prepared at 1 mg/mL in DMSO (DTG), 
methanol (DRV, EFV, MRV), and water (RAL, 3TC) and serially diluted in 70:30 methanol/
water to cover an analytical range of 0.06–150 ng/sample. Extraction efficiency was 
evaluated based on analyte recovery from serial extraction of hair strands.12 Precision and 
accuracy of the calibration standards and QC samples were within acceptance criteria of 
20%.
RESULTS AND DISCUSSION
Optimization of IR-MALDESI for Hair Analysis
The analytical response of IR-MALDESI is sensitive to a range of variables in its 
experimental geometry controlling sample desorption and ionization, which have been 
previously optimized for interrogation of tissue cryosections.53 Intact hair strands, roughly 
80 µm in diameter and consisting of three distinct layers (cuticle, cortex, and medulla), 
present a distinct morphology relative to tissue cryosections. While incorporation of drug 
into hair can occur from the exterior cuticle layer through exposure to sweat and sebum, 
incorporation from blood occurs during follicular cell development and concentrates in the 
cortex.9 MSI analysis of hair strands using UV lasers, with depth penetration on the order 
tens of nanometers,54 typically includes preprocessing steps to facilitate probing analytes 
localized within the cortex either through solvent extraction25 or by longitudinally 
sectioning27 and abraiding28 individual strands to expose the cortex directly. These methods 
add both labor and time to the analysis process, while also introducing the potential for 
sample contamination28 and analyte delocalization25 that may compromise the temporal 
record of drug use. Given the greater penetration depth (micrometers) of IR lasers into 
biological samples,54 we sought to develop an IR-MALDESI analysis method for hair that 
did not require sample manipulation. We first investigated the extent to which the unique 
morphology of hair strands required different IR-MALDESI desorption conditions (sample 
height, laser fluence, and number of laser shots per voxel) than tissue to optimize response 
to ARVs. Hair strands incubated in EFV were used as a test matrix. Although the radial 
distribution of drug in hair may vary between incubated strands (where external drug 
solution is absorbed through the exterior of the strand) and physiologically incorporated 
strands, incubated strands have the advantage of representing a controlled reference sample 
in which drug is expected to be uniformly distributed for calibration of MSI response in 
quantitative hair analysis.25 A representative optical image of a hair strand analyzed by IR-
MALDESI can be seen in Figure 1A. The image shows a region of the strand that has not 
been analyzed, in which the pigmented, optically translucent strand with darker medulla 
layer is clearly visible. While profilometry measuring the laser penetration depth was not 
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performed, the change in opacity of the medulla and surrounding strand suggests that 
infrared laser desorption penetrates through the cuticle layer and potentially the cortex layer 
as well. Figure 1B shows ion maps of cholesterol ([M + H − H2O]+, m/z 369.3516) and EFV 
([M + H]+, m/z 316.0347) from IR-MALDESI analysis of incubated hair strands analyzed 
with varying numbers of laser shots (1–5) acquired at each volumetric element, or voxel, 
probed by the laser. Average ion abundances of EFV and endogenous lipids indicated that 
two laser shots per voxel, with a laser pulse of 0.6 mJ/pulse, yielded the best IR-MALDESI 
response to analytes in hair. Since the strand is not completely ablated with <5 laser pulses, 
the preference for two laser pulses may reflect the concentration of incorporated EFV closer 
to the surface of the strand or may also be a result of unfavorable effects on analyte ion 
abundance recently shown to occur as the C-trap accumulation time is extended to 
accommodate a greater number of laser pulses.42 Reanalysis of a hair strand by IR-
MALDESI, profiling a region in which the cuticle and some of the cortical layer had been 
previously removed by laser desorption, indicated a ~60% reduction in signal abundance of 
EFV (Figure S-1). This suggests that approximately 80%, as an upper bound, of 
accumulated EFV is extracted from incubated hair strands during initial IR-MALDESI 
analysis of intact hair.
Calibration of IR-MALDESI Response to ARVs in Incubated Hair and Correlation to LC–
MS/MS
Using conditions yielding the best response to incubated strands, a calibration was 
performed of IR-MALDESI response to hair strands incubated in six ARVs: EFV, DTG, 
DRV, RAL, MRV, and 3TC. These ARVs, summarized in Table S-1, represent a range of 
drug classes often utilized in HIV treatment and which possess different basicity and 
lipophilicity controlling their incorporation into hair. Hair strands were incubated in a 3-log 
concentration range (1, 10, 100 µg/mL solutions) of the six ARVs as described above. 
Representative hair IR-MALDESI ion maps of ARV distribution in hair for EFV can be seen 
in Figure 2A for each of the three incubated drug concentrations. The averaged ion 
abundance of the ARVs from five individual strands measured by IR-MALDESI was 
compared to LC–MS/MS response, where the amount of drug in fixed segment lengths of 
individual strands is estimated based on hair mass using an average hair density (0.633 g/
cm3) and hair diameter (80 µm).25 A complete summary of calibration data including linear 
plots of IR-MALDESI response to each of the six ARVs and blank samples can be found in 
the Supporting Information (Table S-2 and Figure S-2). These data are shown in Figure 2B, 
plotted on a log–log scale to allow IR-MALDESI response to all ARVs to be seen easily. 
Data are color-coded by available information on drug pKa,55–60 increasing in shade from 
3TC (pKa = 4.3)60 to EFV (pKa = 10.2).56 Focusing on the cross-hatched data points, 
representing the lowest incubation concentration for each of the ARVs, it is observed that the 
amount of drug penetrating into hair strands as quantified by LC–MS/MS tends to increase 
with reported pKa. The range of ARV concentrations in incubated strands scales in a similar 
manner, increasing from 3TC (1.00–61.76 ng/mg hair) to EFV (24.34–1772.58 ng/mg hair). 
LC–MS/MS extraction efficiencies for each ARV from incubated strands were estimated to 
be 86% or higher. A linear relationship (R2 > 0.962) between IR-MALDESI response and 
LC–MS/MS exists over the entire range of concentrations for each ARV with the exception 
of DTG (R2 = 0.645), as summarized in Table S-3. Intercept values for linear regressions 
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exceed IR-MALDESI response to blank samples, particularly for RAL, EFV, and DTG. Fits 
for these higher accumulating ARVs may be influenced by ion losses due to space 
charging49 at the high end of the calibration range, where high IR-MALDESI ion abundance 
(>106) and variability are seen, at incubated hair concentrations greater than 300 ng/mg hair. 
Accumulation of ARVs in dosed hair is typically below 100–150 ng/mg hair,14–16,61,62 and 
IR-MALDESI response to all six ARVs is highly linear (R2 > 0.984) over this range (Figure 
S-2).49
IR-MALDESI signal abundance for a given analyte concentration varies according to the 
ionization efficiency of the analyte in the electrospray,33 and the current MSI conditions 
indicate an increase in sensitivity from MRV > DTG > RAL > 3TC > DRV > EFV based on 
calibration slope. Limits of detection (LOD) were not reached experimentally for any of the 
six ARVs over the 3-log range in drug concentrations used for incubating hair strands but 
have been estimated to be less than or equal to 1.6 ng/mg hair based on the calibration and 
response to blank hair strands (Table S3). A systematic determination of instrumental LOD 
will be the focus of future work targeting ARV analysis in hair.
IR-MALDESI Response to ARVs in Dosed Hair
Brown hair strands cut from the scalp of three HIV infected, virologically suppressed 
subjects receiving fixed-dose Atripla (a combination of EFV, FTC, and prodrug form of 
TFV) for ≥1 year, were evaluated to determine interpatient and intrapatient variability in IR-
MALDESI response. MSI analysis was simultaneously performed on 5–10 single hair 
strands from each HIV positive donor on ARV therapy to account for natural variability in 
hair growth cycles that can influence the accumulation of drug, with up to 20% of scalp hair 
in the dormant telogen phase as well as incubated strands used as positive controls. The 
resulting ion maps, Figure 3A, showed continuous distribution of EFV response across the 
entirety of each strand of hair without detectable gaps, indicating uninterrupted dosing in 
accordance with the condition of virologic suppression measured by PCR by which these 
patients were classified as adherent. MS2I of dosed and incubated hair strands by IR-
MALDESI confirmed the unique assignment of EFV based on known transition patterns.63 
The MSiSlicer feature of MSiReader allows visualization and interpretation of ion 
abundance along the curvilinear path of a hair strand. Figure 3B shows the temporal profile 
of EFV over 3 mm of a hair strand from Patient 1 starting at the proximal end, 
corresponding to approximately 9 days of hair growth. Pervoxel MSI response was evaluated 
using MSiReader software and average response for each patient is summarized in Figure 
3A. Average IR-MALDESI response to multiple strands from individual donors indicated 
high repeatability (<12% relative standard deviation, % RSD) of response and a ~1.4-fold 
intrapatient variability in IR-MALDESI EFV ion abundance. A ~4-fold interpatient 
variability was observed. These results were in good agreement with LC–MS/MS analysis of 
extracts from matching single strands, Figure S-3, which indicated a ~2.3-fold interpatient 
variability in EFV (mean =1.720 ng/mg hair, range = 0.968–2.200 ng/mg hair). LC–MS/MS 
extraction efficiency for EFV from dosed hair was estimated to be 91% based on serial 
extraction of hair strands. No detectable response to TFV or FTC was observed by IR-
MALDESI MSI from dosed patient samples. LC–MS/MS analysis of extracts from 
matching single strands indicated that FTC (mean = 0.333 ng/mg hair, range = 0.213–0.535 
Rosen et al. Page 8
Anal Chem. Author manuscript; available in PMC 2017 February 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ng/mg hair) was present in the hair strands at concentrations below EFV and that TFV was 
below the limit of quantitation. TFV (pKa = 3.75) and FTC (pKa = 2.7) accumulate at low 
levels in hair and typically require large thatches of hair for quantitative analysis.14
Given that IR-MALDESI sensitivity toward EFV in hair was lower than other relevant ARVs 
calibrated in this work and that the method was capable of evaluating the longitudinal 
distribution of EFV at concentrations typically observed for ARVs in hair,14–16,61,62 we 
anticipate that this approach has broad applicability for monitoring the disposition of ARVs 
in hair samples collected from patients. While MSI sample preparation has been minimized 
to reduce processing time and avoid axial and transverse analyte delocalization25 and 
compromise the temporal record of drug use, solvent extraction25 and longitudinal 
sectioning27 steps will likely be explored in future analysis to improve limits of quantitation 
when targeting lower accumulating compounds. Since all patients examined were on the 
same fixed dose regimen of EFV, differences in the response observed in hair between 
patients may arise from metabolism or physiological incorporation into the hair strands. 
While explicating the contributing sources of these differences was beyond the scope of the 
current work, an approach to normalizing analyte response using a marker for melanin 
content is discussed in the next section.
Evaluating Hair Melanin Content by MSI
Drug response in hair can vary greatly depending on hair pigmentation, treatment, and 
texture. Cosmetic and ultrastructural alterations to hair through treatments such as bleaching 
and dyeing have been shown to reduce the presence of drug in hair.64,65 The amount of drug 
incorporated in hair can correlate strongly to melanin content based on drug basicity,35,37 
and is likely one of the factors contributing to differences in EFV response observed 
between patients in the previous section. While Poetzsch et al. have recently demonstrated 
that melanin does not influence the ionization process of UV MALDI,25 development of an 
MSI method to evaluate hair melanin content is needed to facilitate comparison in drug 
accumulation between different subjects, a necessity for an assessment of adherence based 
strictly on dose–response. Eumelanin, the predominate polymeric form of melanin, is 
composed mainly of the monomer unit 5,6-dihydroxyindole-2-carboxylic acid (DHICA). A 
common strategy for quantification of eumelanin involves the chemical oxidation of DHICA 
to PTCA,39–41 as shown in Figure 4A. On the basis of the method of Szekely-Klepser et 
al.,40 hair strands of different colors from multiple donors were adhered to a glass slide and 
15% H2O2 was uniformly sprayed onto the surface of the hair strands. Once wetted, samples 
were allowed to incubate overnight prior to analysis. Targeted negative ion mode MS2I 
monitoring of characteristic PTCA transitions, verified by direct infusion of a PTCA 
reference standard, was conducted on both pigmented and unpigmented hair strands as an 
initial validation step. Ion maps of [PTCA − H]− and fragments associated with the loss of 
one (m/z 154.01330) and two (m/z 110.02320) carboxylic acid units are shown in Figure 4B. 
These ion maps indicate that PTCA and its characteristic fragments were positively 
identified in the four pigmented hair strands analyzed but do not show any presence of the 
ions from gray, unpigmented hair strands (denoted by white asterisks in the overlaid images 
of Figure 4B) and served to confirm the PTCA peak assignment. PTCA response from hair 
strands with a range of pigmentation (blonde, brown, black, dyed) was then evaluated in a 
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full MS polarity switching MSI mode. PTCA ion abundance was observed to increase with 
darkening hair color (Figure 4C), and there is some indication that delocalization of PTCA 
away from the hair strands can occur during H2O2 incubation. Average PTCA response 
across each color hair strand is summarized in Figure 4D, with a range of almost an order of 
magnitude differentiating highly pigmented black strands from blonde. Dyed brown, 
chemically altered hair showed very little PTCA ion abundance. Additional assay 
optimization is expected to reduce the intrastrand variability in response (% RSD = 39–
75%).
On the basis of the method for determining hair PTCA response, we evaluated the 
applicability of a normalization scheme for EFV in hair based on melanin content to 
facilitate direct interpatient comparison of drug accumulation. Strands (n = 4) from each of 
the three patients on therapy were first analyzed by IR-MALDESI for response to EFV 
before the strands were sprayed, incubated, and reanalyzed for EFV and PTCA. Optical 
images of the brown hair strands in Figure 5A show the depletion of pigmentation after the 
exposure to H2O2. Also seen in Figure 5A are ion maps of EFV distribution in hair strands, 
which do not indicate a significant difference in EFV ion abundance measured before and 
after exposure to H2O2. While exposure to peroxide-based bleaching creams has recently 
been shown to rapidly degrade the detectability of cocaine in hair during MSI analysis,26 our 
results suggest that analysis of PTCA may be possible while still preserving the integrity of 
a drug bound in hair. Ion abundances of both EFV and PTCA were averaged based on 
longitudinal distance from the proximal end across all strands from each patient. The ion 
map of EFV response and average profiles of EFV distribution from each patient are shown 
in the top panel of Figure 5B, again indicating a 4-fold difference in response between 
Patient 1 and Patient 3 that is in good agreement with the LC–MS/MS response (Figure S-3). 
PTCA response between the brown hair strands from the patients varied (Figure S-4) and 
normalizing the per-voxel ion abundance of EFV ([EFV + H]+) by that of PTCA([PTCA − 
H]−), shown in the middle panel of Figure 5B, causes all profiles of patient response to fixed 
dose therapy to overlap within a standard deviation of measurement. EFV ionizes well in 
both positive and negative ionization modes, allowing us to also investigate normalizing the 
ion abundance of EFV ([EFV − H]−) by PTCA([PTCA − H]−) since we have shown recently 
that the % RSD for a normalization scheme can be sensitive to the ionization mechanism of 
the two ions compared based on potential differences in ionization efficiency.33 The bottom 
panel of Figure 5B shows profiles of [EFV − H]−/PTCA − H]−, yielding similar results to 
[EFV + H]+/PTCA − H]−. This is the first evidence for a normalization approach to MSI 
drug response in hair based on melanin content. Determining the applicability of the 
technique for establishing adherence based on threshold drug response will require a much 
greater sample size of patients in future work, but the approach may hold great promise.
Additionally, imaging dosed hair strands over the range m/z 150–600 in both +ESI and −ESI 
yielded over 1000 peaks uniquely associated with hair. As shown in Figure S-5, the mass 
excess plot of these peaks, representing the difference between the nominal and 
monoisotopic ion mass, indicate a high degree of overlap with the mass excess distribution 
for lipid classes, particularly fatty acyls.66 There is potential for discovery within these data 
of biomarkers for hair pigmentation without the requirement for an oxidation sample step, in 
a similar manner to recent identification of biomarker candidates for aging by MSI.30
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CONCLUSIONS
The application of IR-MALDESI to the analysis of ARVs in hair for the purpose of 
characterizing drug adherence has been successfully demonstrated. Infrared laser desorption 
of hair samples penetrates through the cuticle layer of hair strands, allowing imaging of 
analytes in hair without any sample extraction and very minimal sample preparation for 
rapid analysis. Linear response of IR-MALDESI MSI relative to LC–MS/MS methods was 
observed for a range of HIV ARV agents over a 3-log concentration range. The high spatial 
resolution of IR-MALDESI MSI allows profiling of drug response along individual hair 
strands, offering a retrospective picture of a patient’s drug adherence over a long temporal 
window. An approach to normalizing MSI response to drugs based on native melanin 
content of hair has also been demonstrated, facilitating the development of broadly 
applicable adherence evaluation criteria based solely on drug response.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors gratefully acknowledge financial support received from National Institutes of Health (Grants 
U19AI096113, R01AI111891, R01GM087964, and P30 AI50410).
REFERENCES
1. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dube MP, 
Hwang JY, McCutchan JA. the California Collaborative Treatment Group. AIDS. 1999; 13:1099–
1107. [PubMed: 10397541] 
2. Nieuwkerk PT, Oort FJ. JAIDS J. Acquired Immune Defic. Syndr. 2005; 38:445–448. [PubMed: 
15764962] 
3. Gross R, Bilker WB, Friedman HM, Strom BL. AIDS. 2001; 15:2109–2117. [PubMed: 11684930] 
4. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, 
Safren SA, Ware NC, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR. 
PLoS Med. 2013; 10:e1001511. [PubMed: 24058300] 
5. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, Schwartz K, 
Laborde N, Soto-Torres L. PLoS One. 2014; 9:e89118. [PubMed: 24586534] 
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, 
Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, 
Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, 
Deese J, Crucitti T, Mastro TD, Taylor D, Grp FE-PS. N. Engl. J. Med. 2012; 367:411–422. 
[PubMed: 22784040] 
7. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. AIDS. 2012; 26:F13–F19. [PubMed: 
22333749] 
8. Baumgartner WA, Hill VA, Blahd WH. J. Forensic Sci. 1989; 34:1433–1453.
9. Pragst F, Balikova MA. Clin. Chim. Acta. 2006; 370:17–49. [PubMed: 16624267] 
10. Uematsu T. Clin. Pharmacokinet. 1993; 25:83–87. [PubMed: 8403740] 
11. Beumer JH, Bosman IJ, Maes R. Int. J. Clin. Pract. 2001; 55:353–357. [PubMed: 11501221] 
12. Huang Y, Gandhi M, Greenblatt RM, Gee WN, Lin ET, Messenkoff N. Rapid Commun. Mass 
Spectrom. 2008; 22:3401–3409. [PubMed: 18837069] 
13. Huang Y, Yang QY, Yoon K, Lei Y, Shi R, Gee W, Lin ET, Greenblatt RM, Gandhi M. Anal. 
Bioanal. Chem. 2011; 401:1923–1933. [PubMed: 21847531] 
Rosen et al. Page 11
Anal Chem. Author manuscript; available in PMC 2017 February 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Liu AY, Yang QY, Huang Y, Bacchetti P, Anderson PL, Jin CS, Goggin K, Stojanovski K, Grant R, 
Buchbinder SP, Greenblatt RM, Gandhi M. PLoS One. 2014; 9:e83736. [PubMed: 24421901] 
15. Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, Mattah B, Salmen 
MR, Zoughbie D, Fiorella KJ, Geng E, Njoroge B, Jin CS, Huang Y, Bukusi EA, Cohen CR, 
Gandhi M. JAIDS J. Acquired Immune Defic. Syndr. 2014; 66:311–315. [PubMed: 24694932] 
16. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, Young M, Milam J, Cohen 
MH, Sharp GB, Huang Y, Greenblatt RM. Clin. Infect. Dis. 2011; 52:1267–1275. [PubMed: 
21507924] 
17. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. JAIDS J. Acquired 
Immune Defic. Syndr. 2001; 26:82–92. [PubMed: 11176272] 
18. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, Verdon R. Clin. Infect. Dis. 
2004; 38:1311–1316. [PubMed: 15127346] 
19. Prideaux B, Stoeckli M. J. Proteomics. 2012; 75:4999–5013. [PubMed: 22842290] 
20. Murphy RC, Hankin JA, Barkley RM. J. Lipid Res. 2008; 50(Suppl):S317–S322. [PubMed: 
19050313] 
21. Gode D, Volmer DA. Analyst. 2013; 138:1289–1315. [PubMed: 23314100] 
22. Burnum KE, Frappier SL, Caprioli RM. Annu. Rev. Anal. Chem. 2008; 1:689–705.
23. Greer T, Sturm R, Li LJ. J. Proteomics. 2011; 74:2617–2631. [PubMed: 21515430] 
24. Schwamborn K. J. Proteomics. 2012; 75:4990–4998. [PubMed: 22749859] 
25. Poetzsch M, Steuer AE, Roemmelt AT, Baumgartner MR, Kraemer T. Anal. Chem. 2014; 
86:11758. [PubMed: 25289728] 
26. Cuypers E, Flinders B, Bosman IJ, Lusthof KJ, Van Asten AC, Tytgat J, Heeren RMA. Forensic 
Sci. Int. 2014; 242:103–110. [PubMed: 25047217] 
27. Nakanishi T, Nirasawa T, Takubo T. J. Anal. Toxicol. 2014; 38:349–353. [PubMed: 24802158] 
28. Shen M, Xiang P, Shi Y, Pu H, Yan H, Shen BH. Anal. Bioanal. Chem. 2014; 406:4611–4616. 
[PubMed: 24906693] 
29. Porta T, Grivet C, Kraemer T, Varesio E, Hopfgartner G. Anal. Chem. 2011; 83:4266–4272. 
[PubMed: 21510611] 
30. Waki ML, Onoue K, Takahashi T, Goto K, Saito Y, Inami K, Makita I, Angata Y, Suzuki T, 
Yamashita M, Sato N, Nakamura S, Yuki D, Sugiura Y, Zaima N, Goto-Inoue N, Hayasaka T, 
Shimomura Y, Setou M. PLoS One. 2011; 6:e26721. [PubMed: 22039541] 
31. Robichaud G, Barry JA, Garrard KP, Muddiman DC. J. Am. Soc. Mass Spectrom. 2013; 24:92–
100. [PubMed: 23208743] 
32. Barry JA, Robichaud G, Bokhart MT, Thompson C, Sykes C, Kashuba ADM, Muddiman DC. J. 
Am. Soc. Mass Spectrom. 2014; 25:2038–2047. [PubMed: 24744212] 
33. Bokhart M, Rosen E, Thompson C, Sykes C, Kashuba AM, Muddiman D. Anal. Bioanal. Chem. 
2015; 407:2073–2084. [PubMed: 25318460] 
34. Thompson CG, Bokhart MT, Sykes C, Adamson L, Fedoriw Y, Luciw PA, Muddiman DC, 
Kashuba ADM, Rosen EP. Antimicrob. Agents Chemother. 2015; 59:2944–2948. [PubMed: 
25733502] 
35. Rollins DE, Wilkins DG, Krueger GG, Augsburger MP, Mizuno A, O’Neal C, Borges CR, Slawson 
MH. J. Anal. Toxicol. 2003; 27:545–551. [PubMed: 14670132] 
36. Slawson MH, Wilkins DC, Rollins DE. J. Anal. Toxicol. 1998; 22:406–413. [PubMed: 9788513] 
37. Kronstrand R, Forstberg-Peterson S, Kagedal B, Ahlner J, Larson G. Clin. Chem. 1999; 45:1485–
1494. [PubMed: 10471651] 
38. Henderson GL, Harkey MR, Zhou CH, Jones RT, Jacob P. J. Anal. Toxicol. 1998; 22:156–165. 
[PubMed: 9547413] 
39. Ito S, Wakamatsu K. Pigm. Cell Res. 2003; 16:523–531.
40. Szekely-Klepser G, Wade K, Woolson D, Brown R, Fountain S, Kindt E. J. Chromatogr. B. Anal. 
Technol. Biomed. Life Sci. 2005; 826:31–40.
41. Panzella L, Manini P, Monfrecola G, d’Ischia M, Napolitano A. Pigm. Cell Res. 2007; 20:128–133.
Rosen et al. Page 12
Anal Chem. Author manuscript; available in PMC 2017 February 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
42. Rosen EP, Bokhart MT, Nazari M, Muddiman DC. Anal. Chem. 2015; 87:10483–10490. [PubMed: 
26414177] 
43. Robichaud G, Barry JA, Muddiman DC. J. Am. Soc. Mass Spectrom. 2014; 25:319–328. [PubMed: 
24385399] 
44. Sampson JS, Hawkridge AM, Muddiman DC. J. Am. Soc. Mass Spectrom. 2006; 17:1712–1716. 
[PubMed: 16952462] 
45. Rosen EP, Bokhart MT, Ghashghaei HT, Muddiman DC. J. Am. Soc. Mass Spectrom. 2015; 
26:899–910. [PubMed: 25840812] 
46. Cochran K, Barry J, Robichaud G, Muddiman D. Anal. Bioanal. Chem. 2015; 407:813–820. 
[PubMed: 25081013] 
47. Nazari M, Muddiman DC. Analyst. 2016
48. Jurchen JC, Rubakhin SS, Sweedler JV. J. Am. Soc. Mass Spectrom. 2005; 16:1654–1659. 
[PubMed: 16095912] 
49. Olsen JV, de Godoy LMF, Li GQ, Macek B, Mortensen P, Pesch R, Makarov A, Lange O, Horning 
S, Mann M. Mol. Cell. Proteomics. 2005; 4:2010–2021. [PubMed: 16249172] 
50. Kessner D, Chambers M, Burke R, Agus D, Mallick P. Bioinformatics. 2008; 24:2534–2536. 
[PubMed: 18606607] 
51. Race AM, Styles IB, Bunch J. J. Proteomics. 2012; 75:5111–5112. [PubMed: 22641155] 
52. Robichaud G, Garrard K, Barry J, Muddiman D. J. Am. Soc. Mass Spectrom. 2013; 24:718–721. 
[PubMed: 23536269] 
53. Robichaud G, Barry J, Muddiman D. J. Am. Soc. Mass Spectrom. 2014:1–10. [PubMed: 
24249043] 
54. Dreisewerd K. Chem. Rev. 2003; 103:395–426. [PubMed: 12580636] 
55. ChemAxon. [accessed October 8, 2015] http://www.chemicalize.org. 
56. Kashuba ADM, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antimicrob. Agents 
Chemother. 1999; 43:1817–1826. [PubMed: 10428898] 
57. ViiV Healthcare Group. 2015 Retrieved from http://www.medicines.org.au/files/viptivic.pdf. 
58. Moss DM, Siccardi M, Murphy M, Piperakis MM, Khoo SH, Back DJ, Owen A. Antimicrob. 
Agents Chemother. 2012; 56:3020–3026. [PubMed: 22450971] 
59. Abel S, Back DJ, Vourvahis M. Antiviral Therapy. 2009; 14:607–618. [PubMed: 19704163] 
60. Shalaeva M, Kenseth J, Lombardo F, Bastin A. J. Pharm. Sci. 2008; 97:2581–2606. [PubMed: 
18228610] 
61. Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, Horng H, Clark TD, 
Plenty A, Ruel TD, Achan J, Charlebois ED, Kamya MR, Havlir DV, Gandhi M. AIDS. 2015; 
29:825–830. [PubMed: 25985404] 
62. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, 
Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D, Prevention M, Toror 
HIVD. JAIDS J. Acquired Immune Defic. Syndr. 2013; 63:578–584. [PubMed: 24135775] 
63. Nirogi R, Bhyrapuneni G, Kandikere V, Mudigonda K, Komarneni P, Aleti R, Mukkanti K. 
Biomed. Chromatogr. 2009; 23:371–381. [PubMed: 18937306] 
64. Potsch L, Skopp G, Becker J. Int. J. Legal Med. 1995; 107:301–305. [PubMed: 7577693] 
65. Jurado C, Kintz P, Menendez M, Repetto M. International Journal of Legal Medicine. 1997; 
110:159–163. [PubMed: 9228567] 
66. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, Glass CK, Merrill AH Jr, Murphy RC, Raetz CR, 
Russell DW, Subramaniam S. Nucleic Acids Res. 2007; 35:D527–D532. [PubMed: 17098933] 
Rosen et al. Page 13
Anal Chem. Author manuscript; available in PMC 2017 February 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Optimization of IR-MALDESI analysis of hair strands. (A) Optical image of hair strand 
indicating laser desorption of material in region analyzed by IR-MALDESI. (B) Ion maps of 
an endogenous lipid, cholesterol, and incubated ARV efavirenz collected with varying 
numbers of laser pulses (1–5) at each voxel.
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Figure 2. 
Calibration of IR-MALDESI MSI response to ARV-incubated hair strands. (A) IR-
MALDESI ion maps of EFV response, representative of other investigated ARVs, from 
strands incubated in stock solution concentrations of 1 µg/mL, 10 µg/mL, and 100 µg/mL as 
noted in each panel. (B) Log–log plot summarizing +ESI IRMALDESI response to all six 
ARVs relative to LC–MS/MS measurements of ARV accumulation from incubated hair 
strands. Linear plots comparing IR-MALDESI and LC–MS/MS results for each individual 
analyte are shown in the Supporting Information, Figure S-1.
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Figure 3. 
Analysis of EFV in hair strands from three dosed patients. (A) IR-MALDESI MSI shows 
uniform longitudinal distribution of EFV in hair strands collected from virally suppressed 
dosed patients, with high intrapatient repeatability of response. (B) Longitudinal profiling of 
EFV response from proximal end of dosed hair strands using MSiReader.
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Figure 4. 
(A) Scheme of melanin degradation to analytical target PTCA based on hair oxidation by 
15% H2O2 and 1 M NH4OH. (B) −ESI IR-MALDESI MS2I ion maps of [PTCA − H]− (m/z 
198.0039) and fragments associated with the loss of one (m/z 154.01330) and two (m/z 
110.02320) carboxylic acid units from oxidized pigmented and unpigmented hair strands. 
Unpigmented, gray strands (denoted by white asterisks) show no response to PTCA. (C) Ion 
map of PTCA response from hair strands varying in color (dyed, blonde, brown, and black). 
D) Average [PTCA − H]− ion abundance from colored hair strands indicating increased 
abundance as hair color darkens.
Rosen et al. Page 17
Anal Chem. Author manuscript; available in PMC 2017 February 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. 
(A) IR-MALDESI response to [EFV + H]+ from strands (n = 4) of three dosed patients 
before (left) and after (right) oxidation of melanin by H2O2 indicating no significant 
degradation in response to EFV. (B) Top panel: ion map of [EFV + H]+ (left) and average 
longitudinal profile (right) for each of three patients, indicating a 4-fold difference in 
response to accumulated EFV in hair. Middle panel: Normalization of [EFV + H]+ response 
by [PTCA − H]− results in similar longitudinal profiles for each of three patients to fixed-
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dose intake of EFV. Bottom panel: Comparative normalization approach for EFV, matching 
ionization mechanisms ([EFV − H]−/PTCA − H]−).
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